Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Quantifying Cancer Epithelial-Mesenchymal Plasticity and its Association with Stemness and Immune Response.

Jia D, Li X, Bocci F, Tripathi S, Deng Y, Jolly MK, Onuchic JN, Levine H.

J Clin Med. 2019 May 22;8(5). pii: E725. doi: 10.3390/jcm8050725. Review.

2.

Interconnected feedback loops among ESRP1, HAS2, and CD44 regulate epithelial-mesenchymal plasticity in cancer.

Jolly MK, Preca BT, Tripathi SC, Jia D, George JT, Hanash SM, Brabletz T, Stemmler MP, Maurer J, Levine H.

APL Bioeng. 2018 Aug 22;2(3):031908. doi: 10.1063/1.5024874. eCollection 2018 Sep.

3.

E-Cadherin Represses Anchorage-Independent Growth in Sarcomas through Both Signaling and Mechanical Mechanisms.

Jolly MK, Ware KE, Xu S, Gilja S, Shetler S, Yang Y, Wang X, Austin RG, Runyambo D, Hish AJ, Bartholf DeWitt S, George JT, Kreulen RT, Boss MK, Lazarides AL, Kerr DL, Gerber DG, Sivaraj D, Armstrong AJ, Dewhirst MW, Eward WC, Levine H, Somarelli JA.

Mol Cancer Res. 2019 Jun;17(6):1391-1402. doi: 10.1158/1541-7786.MCR-18-0763. Epub 2019 Mar 12.

PMID:
30862685
4.

Structural and Dynamical Order of a Disordered Protein: Molecular Insights into Conformational Switching of PAGE4 at the Systems Level.

Lin X, Kulkarni P, Bocci F, Schafer NP, Roy S, Tsai MY, He Y, Chen Y, Rajagopalan K, Mooney SM, Zeng Y, Weninger K, Grishaev A, Onuchic JN, Levine H, Wolynes PG, Salgia R, Rangarajan G, Uversky V, Orban J, Jolly MK.

Biomolecules. 2019 Feb 22;9(2). pii: E77. doi: 10.3390/biom9020077.

5.

An Integrative Systems Biology and Experimental Approach Identifies Convergence of Epithelial Plasticity, Metabolism, and Autophagy to Promote Chemoresistance.

Xu S, Ware KE, Ding Y, Kim SY, Sheth MU, Rao S, Chan W, Armstrong AJ, Eward WC, Jolly MK, Somarelli JA.

J Clin Med. 2019 Feb 7;8(2). pii: E205. doi: 10.3390/jcm8020205.

6.

Spleen Tyrosine Kinase-Mediated Autophagy Is Required for Epithelial-Mesenchymal Plasticity and Metastasis in Breast Cancer.

Shinde A, Hardy SD, Kim D, Akhand SS, Jolly MK, Wang WH, Anderson JC, Khodadadi RB, Brown WS, George JT, Liu S, Wan J, Levine H, Willey CD, Krusemark CJ, Geahlen RL, Wendt MK.

Cancer Res. 2019 Apr 15;79(8):1831-1843. doi: 10.1158/0008-5472.CAN-18-2636. Epub 2019 Feb 7.

PMID:
30733195
7.

Computational Modeling of the Crosstalk Between Macrophage Polarization and Tumor Cell Plasticity in the Tumor Microenvironment.

Li X, Jolly MK, George JT, Pienta KJ, Levine H.

Front Oncol. 2019 Jan 23;9:10. doi: 10.3389/fonc.2019.00010. eCollection 2019.

8.

Quantitative Characteristic of ncRNA Regulation in Gene Regulatory Networks.

Bocci F, Jolly MK, Levine H, Onuchic JN.

Methods Mol Biol. 2019;1912:341-366. doi: 10.1007/978-1-4939-8982-9_14.

PMID:
30635901
9.

The DNA Walk and its Demonstration of Deterministic Chaos- Relevance to Genomic Alterations in Lung Cancer.

Hewelt B, Li H, Jolly MK, Kulkarni P, Mambetsariev I, Salgia R.

Bioinformatics. 2019 Jan 7. doi: 10.1093/bioinformatics/bty1021. [Epub ahead of print]

PMID:
30615123
10.

Toward understanding cancer stem cell heterogeneity in the tumor microenvironment.

Bocci F, Gearhart-Serna L, Boareto M, Ribeiro M, Ben-Jacob E, Devi GR, Levine H, Onuchic JN, Jolly MK.

Proc Natl Acad Sci U S A. 2019 Jan 2;116(1):148-157. doi: 10.1073/pnas.1815345116. Epub 2018 Dec 26.

PMID:
30587589
11.

Testing the gene expression classification of the EMT spectrum.

Jia D, George JT, Tripathi SC, Kundnani DL, Lu M, Hanash SM, Onuchic JN, Jolly MK, Levine H.

Phys Biol. 2019 Jan 18;16(2):025002. doi: 10.1088/1478-3975/aaf8d4.

PMID:
30557866
12.

Stability and mean residence times for hybrid epithelial/mesenchymal phenotype.

Biswas K, Jolly MK, Ghosh A.

Phys Biol. 2019 Jan 29;16(2):025003. doi: 10.1088/1478-3975/aaf7b7.

PMID:
30537698
13.

Chronic Obstructive Pulmonary Disease and Lung Cancer: Underlying Pathophysiology and New Therapeutic Modalities.

Eapen MS, Hansbro PM, Larsson-Callerfelt AK, Jolly MK, Myers S, Sharma P, Jones B, Rahman MA, Markos J, Chia C, Larby J, Haug G, Hardikar A, Weber HC, Mabeza G, Cavalheri V, Khor YH, McDonald CF, Sohal SS.

Drugs. 2018 Nov;78(16):1717-1740. doi: 10.1007/s40265-018-1001-8. Review.

PMID:
30392114
14.

Hybrid epithelial/mesenchymal phenotypes promote metastasis and therapy resistance across carcinomas.

Jolly MK, Somarelli JA, Sheth M, Biddle A, Tripathi SC, Armstrong AJ, Hanash SM, Bapat SA, Rangarajan A, Levine H.

Pharmacol Ther. 2019 Feb;194:161-184. doi: 10.1016/j.pharmthera.2018.09.007. Epub 2018 Sep 28. Review.

PMID:
30268772
15.

A mechanism-based computational model to capture the interconnections among epithelial-mesenchymal transition, cancer stem cells and Notch-Jagged signaling.

Bocci F, Jolly MK, George JT, Levine H, Onuchic JN.

Oncotarget. 2018 Jul 6;9(52):29906-29920. doi: 10.18632/oncotarget.25692. eCollection 2018 Jul 6.

16.
17.

Hybrid epithelial/mesenchymal phenotype(s): The 'fittest' for metastasis?

Jolly MK, Mani SA, Levine H.

Biochim Biophys Acta Rev Cancer. 2018 Dec;1870(2):151-157. doi: 10.1016/j.bbcan.2018.07.001. Epub 2018 Jul 8. Review.

PMID:
29997040
18.

Prostate-Associated Gene 4 (PAGE4): Leveraging the Conformational Dynamics of a Dancing Protein Cloud as a Therapeutic Target.

Salgia R, Jolly MK, Dorff T, Lau C, Weninger K, Orban J, Kulkarni P.

J Clin Med. 2018 Jun 17;7(6). pii: E156. doi: 10.3390/jcm7060156. Review.

19.

PAGE4 and Conformational Switching: Insights from Molecular Dynamics Simulations and Implications for Prostate Cancer.

Lin X, Roy S, Jolly MK, Bocci F, Schafer NP, Tsai MY, Chen Y, He Y, Grishaev A, Weninger K, Orban J, Kulkarni P, Rangarajan G, Levine H, Onuchic JN.

J Mol Biol. 2018 Aug 3;430(16):2422-2438. doi: 10.1016/j.jmb.2018.05.011. Epub 2018 Jun 5.

PMID:
29758263
20.

Phenotypic Plasticity, Bet-Hedging, and Androgen Independence in Prostate Cancer: Role of Non-Genetic Heterogeneity.

Jolly MK, Kulkarni P, Weninger K, Orban J, Levine H.

Front Oncol. 2018 Mar 6;8:50. doi: 10.3389/fonc.2018.00050. eCollection 2018. Review.

21.

XIAP Regulation by MNK Links MAPK and NFκB Signaling to Determine an Aggressive Breast Cancer Phenotype.

Evans MK, Brown MC, Geradts J, Bao X, Robinson TJ, Jolly MK, Vermeulen PB, Palmer GM, Gromeier M, Levine H, Morse MA, Van Laere SJ, Devi GR.

Cancer Res. 2018 Apr 1;78(7):1726-1738. doi: 10.1158/0008-5472.CAN-17-1667. Epub 2018 Jan 19.

22.

Numb prevents a complete epithelial-mesenchymal transition by modulating Notch signalling.

Bocci F, Jolly MK, Tripathi SC, Aguilar M, Hanash SM, Levine H, Onuchic JN.

J R Soc Interface. 2017 Nov;14(136). pii: 20170512. doi: 10.1098/rsif.2017.0512.

23.

Survival Outcomes in Cancer Patients Predicted by a Partial EMT Gene Expression Scoring Metric.

George JT, Jolly MK, Xu S, Somarelli JA, Levine H.

Cancer Res. 2017 Nov 15;77(22):6415-6428. doi: 10.1158/0008-5472.CAN-16-3521. Epub 2017 Sep 25.

24.

Inflammatory breast cancer: a model for investigating cluster-based dissemination.

Jolly MK, Boareto M, Debeb BG, Aceto N, Farach-Carson MC, Woodward WA, Levine H.

NPJ Breast Cancer. 2017 Jun 6;3:21. doi: 10.1038/s41523-017-0023-9. eCollection 2017.

25.

Epithelial-mesenchymal transition, a spectrum of states: Role in lung development, homeostasis, and disease.

Jolly MK, Ward C, Eapen MS, Myers S, Hallgren O, Levine H, Sohal SS.

Dev Dyn. 2018 Mar;247(3):346-358. doi: 10.1002/dvdy.24541. Epub 2017 Jul 21. Review.

26.

MCAM Mediates Chemoresistance in Small-Cell Lung Cancer via the PI3K/AKT/SOX2 Signaling Pathway.

Tripathi SC, Fahrmann JF, Celiktas M, Aguilar M, Marini KD, Jolly MK, Katayama H, Wang H, Murage EN, Dennison JB, Watkins DN, Levine H, Ostrin EJ, Taguchi A, Hanash SM.

Cancer Res. 2017 Aug 15;77(16):4414-4425. doi: 10.1158/0008-5472.CAN-16-2874. Epub 2017 Jun 23.

27.

Phenotypic Plasticity and Cell Fate Decisions in Cancer: Insights from Dynamical Systems Theory.

Jia D, Jolly MK, Kulkarni P, Levine H.

Cancers (Basel). 2017 Jun 22;9(7). pii: E70. doi: 10.3390/cancers9070070. Review.

28.

Epithelial/mesenchymal plasticity: how have quantitative mathematical models helped improve our understanding?

Jolly MK, Tripathi SC, Somarelli JA, Hanash SM, Levine H.

Mol Oncol. 2017 Jul;11(7):739-754. doi: 10.1002/1878-0261.12084. Epub 2017 Jun 19. Review.

29.

EMT and MET: necessary or permissive for metastasis?

Jolly MK, Ware KE, Gilja S, Somarelli JA, Levine H.

Mol Oncol. 2017 Jul;11(7):755-769. doi: 10.1002/1878-0261.12083. Epub 2017 Jun 12. Review.

30.

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells.

Ware KE, Gilja S, Xu S, Shetler S, Jolly MK, Wang X, Bartholf Dewitt S, Hish AJ, Jordan S, Eward W, Levine H, Armstrong AJ, Somarelli JA.

J Vis Exp. 2017 Apr 7;(122). doi: 10.3791/55520.

31.

Operating principles of tristable circuits regulating cellular differentiation.

Jia D, Jolly MK, Harrison W, Boareto M, Ben-Jacob E, Levine H.

Phys Biol. 2017 May 23;14(3):035007. doi: 10.1088/1478-3975/aa6f90.

PMID:
28443829
32.

Phosphorylation-induced conformational dynamics in an intrinsically disordered protein and potential role in phenotypic heterogeneity.

Kulkarni P, Jolly MK, Jia D, Mooney SM, Bhargava A, Kagohara LT, Chen Y, Hao P, He Y, Veltri RW, Grishaev A, Weninger K, Levine H, Orban J.

Proc Natl Acad Sci U S A. 2017 Mar 28;114(13):E2644-E2653. doi: 10.1073/pnas.1700082114. Epub 2017 Mar 13.

33.

The GRHL2/ZEB Feedback Loop-A Key Axis in the Regulation of EMT in Breast Cancer.

Mooney SM, Talebian V, Jolly MK, Jia D, Gromala M, Levine H, McConkey BJ.

J Cell Biochem. 2017 Sep;118(9):2559-2570. doi: 10.1002/jcb.25974. Epub 2017 May 3.

PMID:
28266048
34.

Distinguishing mechanisms underlying EMT tristability.

Jia D, Jolly MK, Tripathi SC, Den Hollander P, Huang B, Lu M, Celiktas M, Ramirez-Peña E, Ben-Jacob E, Onuchic JN, Hanash SM, Mani SA, Levine H.

Cancer Converg. 2017;1(1):2. doi: 10.1186/s41236-017-0005-8. Epub 2017 Nov 1.

35.

Phenotypic plasticity in prostate cancer: role of intrinsically disordered proteins.

Mooney SM, Jolly MK, Levine H, Kulkarni P.

Asian J Androl. 2016 Sep-Oct;18(5):704-10. doi: 10.4103/1008-682X.183570. Review.

36.

Mesenchymal-Epithelial Transition in Sarcomas Is Controlled by the Combinatorial Expression of MicroRNA 200s and GRHL2.

Somarelli JA, Shetler S, Jolly MK, Wang X, Bartholf Dewitt S, Hish AJ, Gilja S, Eward WC, Ware KE, Levine H, Armstrong AJ, Garcia-Blanco MA.

Mol Cell Biol. 2016 Sep 12;36(19):2503-13. doi: 10.1128/MCB.00373-16. Print 2016 Oct 1.

37.

Notch-Jagged signalling can give rise to clusters of cells exhibiting a hybrid epithelial/mesenchymal phenotype.

Boareto M, Jolly MK, Goldman A, Pietilä M, Mani SA, Sengupta S, Ben-Jacob E, Levine H, Onuchic JN.

J R Soc Interface. 2016 May;13(118). pii: 20151106. doi: 10.1098/rsif.2015.1106.

38.

Tumor Budding: The Name is EMT. Partial EMT.

Grigore AD, Jolly MK, Jia D, Farach-Carson MC, Levine H.

J Clin Med. 2016 Apr 29;5(5). pii: E51. doi: 10.3390/jcm5050051. Review.

39.

Stability of the hybrid epithelial/mesenchymal phenotype.

Jolly MK, Tripathi SC, Jia D, Mooney SM, Celiktas M, Hanash SM, Mani SA, Pienta KJ, Ben-Jacob E, Levine H.

Oncotarget. 2016 May 10;7(19):27067-84. doi: 10.18632/oncotarget.8166.

40.

Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome.

Tripathi SC, Peters HL, Taguchi A, Katayama H, Wang H, Momin A, Jolly MK, Celiktas M, Rodriguez-Canales J, Liu H, Behrens C, Wistuba II, Ben-Jacob E, Levine H, Molldrem JJ, Hanash SM, Ostrin EJ.

Proc Natl Acad Sci U S A. 2016 Mar 15;113(11):E1555-64. doi: 10.1073/pnas.1521812113. Epub 2016 Feb 29.

41.

Modeling the Transitions between Collective and Solitary Migration Phenotypes in Cancer Metastasis.

Huang B, Jolly MK, Lu M, Tsarfaty I, Ben-Jacob E, Onuchic JN.

Sci Rep. 2015 Dec 2;5:17379. doi: 10.1038/srep17379.

42.

Coupling the modules of EMT and stemness: A tunable 'stemness window' model.

Jolly MK, Jia D, Boareto M, Mani SA, Pienta KJ, Ben-Jacob E, Levine H.

Oncotarget. 2015 Sep 22;6(28):25161-74. doi: 10.18632/oncotarget.4629.

43.

Implications of the Hybrid Epithelial/Mesenchymal Phenotype in Metastasis.

Jolly MK, Boareto M, Huang B, Jia D, Lu M, Ben-Jacob E, Onuchic JN, Levine H.

Front Oncol. 2015 Jul 20;5:155. doi: 10.3389/fonc.2015.00155. eCollection 2015. Review.

44.

Jagged mediates differences in normal and tumor angiogenesis by affecting tip-stalk fate decision.

Boareto M, Jolly MK, Ben-Jacob E, Onuchic JN.

Proc Natl Acad Sci U S A. 2015 Jul 21;112(29):E3836-44. doi: 10.1073/pnas.1511814112. Epub 2015 Jul 7.

45.

OVOL guides the epithelial-hybrid-mesenchymal transition.

Jia D, Jolly MK, Boareto M, Parsana P, Mooney SM, Pienta KJ, Levine H, Ben-Jacob E.

Oncotarget. 2015 Jun 20;6(17):15436-48.

46.

Jagged-Delta asymmetry in Notch signaling can give rise to a Sender/Receiver hybrid phenotype.

Boareto M, Jolly MK, Lu M, Onuchic JN, Clementi C, Ben-Jacob E.

Proc Natl Acad Sci U S A. 2015 Feb 3;112(5):E402-9. doi: 10.1073/pnas.1416287112. Epub 2015 Jan 20.

47.

Towards elucidating the connection between epithelial-mesenchymal transitions and stemness.

Jolly MK, Huang B, Lu M, Mani SA, Levine H, Ben-Jacob E.

J R Soc Interface. 2014 Dec 6;11(101):20140962. doi: 10.1098/rsif.2014.0962.

48.

The three-way switch operation of Rac1/RhoA GTPase-based circuit controlling amoeboid-hybrid-mesenchymal transition.

Huang B, Lu M, Jolly MK, Tsarfaty I, Onuchic J, Ben-Jacob E.

Sci Rep. 2014 Sep 23;4:6449. doi: 10.1038/srep06449.

49.

Toward decoding the principles of cancer metastasis circuits.

Lu M, Jolly MK, Onuchic J, Ben-Jacob E.

Cancer Res. 2014 Sep 1;74(17):4574-87. doi: 10.1158/0008-5472.CAN-13-3367.

50.

Mathematical modeling of sub-cellular asymmetry of fat-dachsous heterodimer for generation of planar cell polarity.

Jolly MK, Rizvi MS, Kumar A, Sinha P.

PLoS One. 2014 May 19;9(5):e97641. doi: 10.1371/journal.pone.0097641. eCollection 2014.

Supplemental Content

Loading ...
Support Center